The role of endocardial catheter ablation in the management of paroxysmal ventricular tachycardia in patient with arrhythmogenic cardiomyopathy
https://doi.org/10.51922/2616-633X.2021.5.2.1298
Abstract
The article describes current approaches to the interventional treatment of patients with arrhythmogenic cardiomyopathy (ACM) complicated with paroxysmal sustained ventricular tachycardia (VT). The advantages and disadvantages of two competing methods for mapping and ablation – activation mapping vs substrate mapping – are analyzed. The rationale for the proposed method of VT substrate mapping in ACM and the authors’ own results are presented. The results obtained by the authors make it possible to recommend substrate ablation according to the proposed technique as an invasive first-line therapy for patients with persistent monomorphic VT and ACM
About the Authors
D. Goncharik
Republican Scientific and Practical Center «Cardiology»
Belarus
Belarus
L. Plashchinskaya
Republican Scientific and Practical Center «Cardiology»
Belarus
Belarus
V. Barsukevich
Republican Scientific and Practical Center «Cardiology»
Belarus
Belarus
A. Chasnoit
Republican Scientific and Practical Center «Cardiology»
Belarus
Belarus
Ye. Rebeko
Republican Scientific and Practical Center «Cardiology»
Belarus
Belarus
M. Zakharevsky
Republican Scientific and Practical Center «Cardiology»
Belarus
Belarus
O. Kovalenko
Republican Scientific and Practical Center «Cardiology»
Belarus
Belarus
References
1. Vaikhanskaya T.G. 1, Sivitskaya L.N. 2, Kurushko T.V. 1, Rusak T.V. 1, Levdansky O.D.2, Danilenko N.G. 2, Davydenko O.G. 2 Change of concept arrhythmogenic cardiomyopathy: expansion of the clinical and genetic spectrum, new criteria for the diagnosis of left ventricular phenotypes. (https://russjcardiol.elpub.ru ISSN 1560-4071 (print) doi: 10.15829/1560-4071-2020-3863). Russian Journal of Cardiology 2020; 25 (10).
2. Priori S.G. et. al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). // European Heart Journal (2015) 36, 2793–2867.
3. Towbin J.A. et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. // Heart Rhythm, Vol 16, No 11, November 2019, E301-372.
4. Deyell M.W. et al. 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Position Statement on the Management of Ventricular Tachycardia and Fibrillation in Patients With Structural Heart Disease. Society Position Statement. //Canadian Journal of Cardiology 2020, V. 36, p. E822-836.
5. Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. // NEJM. 1998 Aug 6. 339(6):364-9.
6. Tabib A, Loire R, Chalabreysse L, et al. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. // Circulation. 2003 Dec 16. 108(24), p. 3000-5.
7. Schinkel AF. Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications. // Circ Arrhythm Electrophysiol 2013;6 p. 562–568.
8. Marcus GM, Glidden DV, Polonsky B. et al. Multidisciplinary Study of Right Ventricular Dysplasia Investigators. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. // J Am Coll Cardiol 2009;54, p. 609–615.
9. Orgeron GM, James CA, Te Riele A, et al. Implantable cardioverter-defibrillator therapy in arrhythmogenic right ventricular dysplasia/cardiomyopathy: predictors of appropriate therapy, outcomes, and complications. // J Am Heart Assoc 2017;6, p. 006242.
10. Link MS, Laidlaw D, Polonsky B, et al. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment. // J Am Coll Cardiol 2014;64, p. 119–125.
11. Corrado D, Leoni L, Link MS, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2003;108, p. 3084–3091.
12. Corrado D, Calkins H, Link MS, et al. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. // Circulation 2010;122, p. 1144–1152.
13. Corrado D, Wichter T, Link MS, et al. Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: An International Task Force Consensus Statement. // Circulation 2015;132, p. 441-53.
14. Køber L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. // N Engl J Med 2016;375:1221-30.
15. Zipse MM, Tzou WS. Sudden cardiac death in nonischemic cardiomyopathy: Refining risk assessment. // J Cardiovasc Electrophysiol 2017;28б p. 1361-6.
16. Link MS, Laidlaw D, Polonsky B, Zareba W, McNitt S, Gear K, Marcus F, Estes NA 3rd. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment. // J Am Coll Cardiol 2014;64, p. 119–125.
17. Hoffmayer KS, Machado ON, Marcus GM, Yang Y, Johnson CJ, Ermakov S, Vittinghoff E, Pandurangi U, Calkins H, Cannom D, Gear KC, Tichnell C, Park Y, Zareba W, Marcus FI, Scheinman MM. Electrocardiographic comparison of ventricular arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy and right ventricular outflow tract tachycardia. // J Am Coll Cardiol 2011;58, p. 831–838.
18. Santangeli P, ZadoES,SuppleGE, etal. Long-termoutcome withcatheterablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy. // Circ Arrhythm Electrophysiol 2015;8, p. 1413–1421.
19. Jiang H, Zhang X, Yang Q, et al. Catheter ablation for ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: a systematic review and meta-analysis. // Acta Cardiol 2016;71, p. 639–649.
20. Cronin E.M. et al. Catheter Ablation of Ventricular Arrhythmias – 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. // Heart Rhythm, Vol 17, No 1, January 2020, p. E1-E154.
21. Tung R et al. Simultaneous Endocardial and Epicardial Delineation of 3D Reentrant Ventricular Tachycardia. // Journal of the American College of Cardiology · Volume 75, Issue 8, 3 March 2020, p. 884-897(https://doi.org/10.1016/j.jacc.2019.12.044.
22. Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357, p. 2657–65. https://doi.org/10.1056/NEJMoa065457].
23. Riley MP, Zado E, Bala R, et al. Lack of uniform progression of endocardial scar in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy and ventricular tachycardia. Circ Arrhythm Electrophysiol, 2010; 3, p. 332–338.
24. Berte B, Sacher F, Venlet J, et al. VT Recurrence after ablation: incomplete ablation or disease progression? A multicentric European study. // J Cardiovasc Electrophysiol 2016;27, p. 80–87.
25. Garcia FC, Bazan V, Zado ES, Ren JF, Marchlinski FE. Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia. // Circulation 2009; 120, p. 366–375.
26. Zudin A.B. Praktika primeneniya distancionnogo obsliuivaniya pacientov v ramkah servisa telemediciny [The practice of using remote patient care within the telemedicine service]. Vestnik Avicenny, 2020, vol. 22, no. 4, pp. 553-557. (in Russian).
Review
For citations:
Goncharik D., Plashchinskaya L., Barsukevich V., Chasnoit A., Rebeko Ye., Zakharevsky M., Kovalenko O. The role of endocardial catheter ablation in the management of paroxysmal ventricular tachycardia in patient with arrhythmogenic cardiomyopathy. Emergency Cardiology and Cardiovascular Risks journal. 2021;5(2):1298–1306. https://doi.org/10.51922/2616-633X.2021.5.2.1298
Views:
23
Email this article 